| Factor Information | |
|---|---|
| Data ID | 3156 |
| Factor | CEC counts in all sampling sites inclduing pulmonary artery, pulmonary vein and peripheral vein |
| Description | CEC=circulating endothelial cell |
| Biomarker | YES |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | The objective of the present study was to identify noninvasive biomarkers of endothelial turnover that could be used to identify congenital heart disease patients at risk of irreversible PAH. |
| p Value | <0.05 |
| Conclusion | Irreversible PAH in congenital heart disease is associated with endothelial damage and with increased circulating endothelial cell counts. The present study suggests that CECs could be a valuable tool to define therapeutic strategies in congenital heart disease patients with PAH. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 656 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | VSD/ASD, VSD/SV/AVSD |
| Reference | |
|---|---|
| PMID | 19139384 |
| Year | 2008 |
| Title | Circulating Endothelial Cells A New Candidate Biomarker of Irreversible Pulmonary Hypertension Secondary to Congenital Heart Disease |
| Sample | ||
|---|---|---|
| Population | children, adolescent and adults | |
| Source | patients' data | |
| Region | Paris, France | |
| Method | 2-way repeated-measure ANOVA | |
| Race | French | |
| Disease History | N/A | |
| Treatment History | sugery | |
| Group | CHD patients with irreversible PAH(Treatment) | CHD patients without PAH(Control) |
| Number | 10 | 5 |
| Age | median age=9 years | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | median=56.7cells/mL (95%CI=26.9-119.8) | median=3.6cells/mL (95%CI=1.3-10.4) |
